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In a traditional randomised clinical trial, patients are
allocated to an experimental treatment or the standard
therapy arm - with equal probability - for its entire
duration. However, using data from past patients to
change allocation probabilities for future patients can
increase the average number of patients who receive the
best treatment. A drawback of doing this is that the
power of the trial can be considerably reduced. The Ber-
noulli Multiarmed bandit problem (MABP) is an idea-
lised model that illustrates such a conflict. For such
model, Gittins & Jones (1974) provided a rule that maxi-
mises the expected patient benefit in a large trial.
Bandit models for clinical trials have been extensively
studied in theory, yet the resulting schemes have been
rarely used in practice. There are many reasons for this,
however the power limitations to detect a significant
treatment effect is a major drawback. In this presenta-
tion, we discuss allocating patients between several
experimental treatments and a shared control group in
a multi-arm trial, using the Gittins index. We modify
the MABP design so that the shared control group is
allocated separately to protect the power of the trial.
The design provides considerable gains not only in effi-
ciency over separate randomised trials but also in the
average proportion of patients allocated to the best
experimental treatment. This design can be advanta-
geously extended for trials in rare diseases, where it
becomes particularly relevant to optimize the choice of
treatment both for patients in the trial and for those to
treat after it.
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